Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Metabolism, Inborn Errors 1Lymphoma, Non-Hodgkin 1Leukemia 1Immunologic Deficiency Syndromes 1Hemoglobinopathies 1Congenital Bone Marrow Failure Syndromes 1Bone Marrow Failure Disorders 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine 4fludarabine phosphate 3Thiotepa 2Melphalan 2Clofarabine 2Busulfan 2AP 1903 reagent 2Tacrolimus 1Mycophenolic Acid 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Cyclosporins 1Cyclophosphamide 1Clinical Trials, Phase I as Topic 1Bone Marrow Transplantation 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemoglobinopathies × Clinical Trials, Phase I as Topic × Classical hematology × Clear all
NCT06839456 2026-04-15

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Children's Hospital of Philadelphia

Phase 1/2 Recruiting
100 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Bone Marrow Failure Disorders, Congenital Bone Marrow Failure Syndromes, Anemia, Refractory, with Excess of Blasts, Hemoglobinopathies, Immunologic Deficiency Syndromes, Leukemia, Lymphoma, Non-Hodgkin, Metabolism, Inborn Errors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡